KalVista Pharmaceuticals (NASDAQ:KALV) Given New $42.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised its price target on KalVista to $42 (from $39) and kept a "buy" rating, implying roughly a 140.77% upside from the stock's current price.
• KalVista reported a strong commercial launch for EKTERLY, generating $49.1 million in revenue over an eight‑month transition period, which the firm says de‑risks the commercial story and supports near‑term revenue guidance.
• Insider activity shows recent insider sales: CEO Benjamin L. Palleiko sold 10,034 shares at about $15.57 (and insiders sold 33,378 shares in the last 90 days), reducing insider ownership to roughly 4.3%.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its target price raised by equities research analysts at Stifel Nicolaus from $39.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the specialty pharmaceutical company's stock. Stifel Nicolaus' price target suggests a potential upside of 140.77% from the stock's current price.

Several other research analysts have also weighed in on KALV. HC Wainwright upped their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a "buy" rating in a research report on Friday, January 9th. TD Cowen restated a "buy" rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Needham & Company LLC lifted their target price on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday. Citizens Jmp dropped their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a report on Thursday. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, December 6th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $32.60.

KalVista Pharmaceuticals Trading Up 1.8%

NASDAQ KALV traded up $0.30 on Thursday, hitting $17.44. 334,136 shares of the stock were exchanged, compared to its average volume of 991,274. The company's 50-day moving average price is $15.87 and its two-hundred day moving average price is $14.41. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals has a 52-week low of $9.23 and a 52-week high of $19.00. The company has a market capitalization of $881.79 million, a price-to-earnings ratio of -4.44 and a beta of -0.35.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 10,034 shares of the company's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $156,229.38. Following the transaction, the chief executive officer directly owned 442,883 shares of the company's stock, valued at approximately $6,895,688.31. This represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul K. Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $83,361.78. Following the sale, the insider directly owned 138,983 shares of the company's stock, valued at approximately $2,163,965.31. The trade was a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $782,000. Invesco Ltd. raised its position in KalVista Pharmaceuticals by 23.1% during the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company's stock valued at $1,258,000 after acquiring an additional 14,621 shares in the last quarter. XTX Topco Ltd bought a new position in KalVista Pharmaceuticals during the fourth quarter valued at approximately $428,000. Vestal Point Capital LP lifted its stake in KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company's stock valued at $30,524,000 after acquiring an additional 1,140,000 shares during the last quarter. Finally, Virtus Investment Advisers LLC lifted its stake in KalVista Pharmaceuticals by 364.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company's stock valued at $653,000 after acquiring an additional 31,721 shares during the last quarter.

Trending Headlines about KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported a strong commercial launch for EKTERLY, posting $49.1 million in EKTERLY revenue during an eight‑month transition period — this provides near‑term sales evidence that de‑risks the commercial story and supports revenue guidance and valuation upside. Article Title
• Positive Sentiment: Company released eight‑months/fiscal‑2025 financial results and a corporate update that reinforced EKTERLY launch momentum and provided operational details investors can use to model near‑term cash flow. Article Title
• Positive Sentiment: Needham raised its price target to $36 and reiterated a Buy rating — the new PT implies meaningful upside (~113% from the ~\$17 area) and signals strong analyst conviction behind the commercial-readout. Article Title
• Neutral Sentiment: Citizens Jmp trimmed its target from $29 to $28 but kept a Market Outperform rating; the cut is small and the firm still sees substantial upside, so this is more of a minor stylistic change than a bearish signal. Article Title
• Neutral Sentiment: Q1/8‑month earnings call transcripts and highlights were posted (useful for modeling and management commentary on pricing, uptake, and margins). Transcripts give detail but no single surprise was reported that would obviously reverse the market move. Article Title Article Title
• Neutral Sentiment: Several short‑interest notices show anomalous/zero values (reports cite a “large increase” but list 0 shares/NaN changes). Given the inconsistent data, there’s no clear short‑pressure signal to interpret from these filings today. (No reliable link available.)

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.